Basic Medical Research Award
John Gurdon and Shinya Yamanaka
For discoveries concerning nuclear reprogramming, the process that instructs specialized adult cells to form early stem cells creating the potential to become any type of mature cell for experimental or therapeutic purposes.
The 2009 Albert Lasker Basic Medical Research Award honors two scientists for their discoveries concerning nuclear reprogramming. This process instructs fully specialized adult cells how to turn into stem cells that can guide the formation of any tissue type. Nuclear reprogramming thus provides the means to create invaluable materials for experimental or therapeutic purposes. In the late 1950s, John Gurdon (Cambridge University) transferred nuclei from adult cells into eggs and showed that the resulting cells took on embryonic characteristics. This advance established that cells retain all of their genes as they specialize and that fully developed cells can be re-set to an embryonic statecontroversial discoveries at the time. Decades later, Shinya Yamanaka (Kyoto University) unlocked a new realm of practical possibilities for nuclear reprogramming when he made adult cells behave like embryonic cells by adding only a few factors. This revelation has offered scientists novel ways to harness and study the powers of embryonic development.
Although much work remains to determine whether nuclear reprogramming techniques will prove safe and effective enough for clinical use, Gurdon's and Yamanaka's discoveries have opened potential avenues toward personalized cell-replacement therapies. Such treatments might offer a means to restore malfunctioning or worn out tissues without subjecting a patient to the risks of immune rejection. Reprogrammed cells also afford novel approaches toward understanding currently inscrutable diseases and for screening drugs to thwart these conditions. Moreover, because scientists can create reprogrammed cells from adult tissue, the technologies come without the controversy that accompanies methods based on embryonic stem cells.
Dormant, but ready for rejuvenation
Biologists have long wondered about the process by which descendants of a single fertilized egg specializeor differentiateto construct an adult animal. Once a skin, muscle, or brain cell commits to its fate, it does not revert to a "totipotent" state, with the potential to become any type of cell. A cell destined to become muscle need not retain its ability to fire neuronal messages, nor must a brain cell remember how to soak up nutrients in the intestine.
This apparently irreversible differentiation could arise from either of two distinct processes. In one, championed by August Weismann in the late 1800s, cells cast off genes as they progress down a particular specialization route; in the other, cells retain their complete collection of genes, but turn them on and off as needed. The first scenario would preclude the possibility of changing one type of mature cell into another because the cell would no longer contain the genetic wherewithal to perform all possible functions. This line of reasoning produced a clear experimental test: Replace an egg's nucleus with that of a specialized cell and assess whether the resulting cell could develop into a complete animal. If so, a nucleus from a fully differentiated cell retains a complete genome, capable of directing all types of specialization.
In 1952, Robert Briggs and Thomas King conducted this experiment with frogs. They transferred nuclei from very early embryosat the so-called blastula stageinto eggs from which they had removed the nuclei. If cells discarded genes when they embarked on the path from zygote to fully developed frog, these nuclei would lack genes necessary to build an animal. Briggs and King found that approximately a third of the transplanted early embryonic nuclei produced normal tadpoles. In contrast, when they repeated the experiment with cells from later stage embryos, the percentage of transplanted nuclei that gave rise to embryos and animals dropped precipitously. The researchers concluded that permanent nuclear changes occur as cells specialize.
In 1956, Gurdon began his graduate work at the University of Oxford with developmental biologist Michail Fischberg. Captivated by the observations of Briggs and King, but cognizant that technical limitations rendered their interpretations debatable, Gurdon repeated their experiments in a different frog, Xenopus laevis, which is easier to work with than the one Briggs and King had used, Rana pipiens. In each study, Gurdon destroyed the nucleus from the recipient cell with UV light and then injected a donor cell's nucleus.
Crucially, Fischberg had discovered a naturally occurring "marker" that allowed Gurdon to distinguish the donated from the recipient nucleus. Nuclei from donor cells carried one rather than two copies of a structure called the nucleolus. This innovation allowed Gurdon to verify whether embryos and animals arose from the transferred nucleus or the failure to inactivate the original one. That proof became essential because, in 1958, his results contradicted those of Briggs and King. He showed that nuclei from cells in late embryonic stages can give rise to apparently normal adult frogs. Many scientists initially doubted Gurdon's results, because they found it hard to believe that a graduate student could overturn the wisdom established by two esteemed developmental biologists. But Gurdon's experimental design was so robust, eventually his data convinced the skeptics.
Gurdon therefore established that the vast majority of the body's cell types retain their genomes as they specialize. Furthermore, the right conditions can awaken genes that have turned idle during development. His discoveries ignited the entire field of nuclear reprogramming and allowed all subsequent work to unfold.
One question remained. Although Gurdon had raised tadpoles from frog cells and generated reproductively competent frogs from fully specialized tadpole cells, he had never produced a fertile adult from the nucleus of an adult cell. In 1997, Keith Campbell and Ian Wilmut (Roslin Institute, Scotland) created Dolly the sheep by transferring into an enucleated egg the nucleus from a mammary gland cell that had been removed from a pregnant ewe. Dolly eventually gave birth to her own lambs, thus closing the experimental gap.
Four factors, a plethora of possibilities
The nuclear reprogramming work raised the possibility of crafting medically useful banks of replacement cells for tired or injured tissue. But such prospects raised challenges. Obtaining human eggs is ethically fraught and technically difficult. Furthermore, cells or tissues derived by such a strategy would be vulnerable to attack by the recipient's genetically unrelated immune system.
In 1999, Shinya Yamanaka began to wonder whether he could devise a nuclear-reprogramming method that would circumvent these hurdles. He knew that the late Harold Weintraub had shown in 1988 that a single gene could convert fibroblasts, a type of connective tissue cell, into muscle cells. If nuclei from fully differentiated cells could be genetically re-set, Yamanaka reasoned, and if one gene could force a certain cell type to behave like another, perhaps he could reprogram adult cells to an embryonic state by adding to them a small number of factors.
As he devised his scheme, he relied heavily on knowledge from the field of embryonic stem (ES) cells, which naturally possess the ability to specialize into any type of adult cell. In the early 1980s, Martin Evans (Lasker Basic Medical Research Award, 2001) figured out how to isolate such cells from mice, grow them in the laboratory, and make animals that are completely composed of their descendants. More than a decade later, James Thomson (University of Wisconsin) took the next step toward potential medical applications when he isolated ES cells from humans.
Yamanaka and colleagues, including graduate student Yoshimi Tokuzawa, compiled a list of 24 genes that had been implicated in maintaining mouse ES cells in an uncommitted state in culture, reasoning that these genes were good candidates for converting fully differentiated cells, such as skin fibroblasts, into ones with multiple possible fates. As a first step, he and his colleagues set up an experimental system that would allow embryonic fibroblasts to survive only if they behaved like ES cells.
In a technical tour de force, Yamanaka and another student, Kazutoshi Takahashi, tested whether the 24 genes, added together, could convert mouse fibroblasts into stem cells that could, in turn, morph into different types of specialized cells. He delivered active versions of these genes, using retroviruses engineered for the purpose. This method generated ES-like cells in 2006 and Yamanaka named them induced pluripotent stem (iPS) cells. He then whittled the group of 24 genes to fourOct3/4, Sox2, c-Myc, and Kif4that, in combination, triggered iPS cell production from embryonic and adult skin fibroblasts. iPS cells resembled ES cells in their appearance and growth characteristics. Furthermore, they displayed molecules characteristic of ES cells. When injected into immunodeficient mice, the iPS cells grew into neural tissue, cartilage, muscle, and forebears of cells that line the intestinal tractrepresenting all classes of tissue that give rise to a complete body. Therefore, iPS cells displayed properties of ES cells in animals as well as in test tubes.
The following year, Yamanaka adjusted his strategy to isolate cells that more closely resemble ES cells. Blastocysts injected with the new, improved iPS cellsbut not with the original onesdeveloped into mice; various organs in the animals carried tissues of iPS origin, indicating that the cells could mature down many physiological paths. Simultaneously, Rudolf Jaenisch (Massachusetts Institute of Technology) and Konrad Hochedlinger (Massachusetts General Hospital) reported similar findings. The Yamanaka experiments were especially notable in that some of his mice grew up to parent offspring that contained iPS-derived cells (see Figure 2). This achievement proved that iPS cells can give rise to all cell typesincluding sperm and eggsrequired for normal adult life.
Only a year after he produced the first iPS cells from adult mouse skin cells, Yamanaka generated iPS cells from adult human skin cells, employing human versions of the same four genes that he had used in the mouse work. Simultaneously, George Daley (Children's Hospital, Boston) and James Thomson achieved similar successes. Yamanaka goaded iPS cells to specialize into neural or cardiac cells in culture. He then wanted to assess whether human iPS cells would differentiate in a live animal. He injected them into immunocompromised mice, where they specialized into the body's main cell types, as the mouse iPS cells had done earlier.
Now, many laboratories worldwide are refining human iPS cell technology and investigating how closely the cells resemble natural ES cells, activities that are necessary to translate nuclear reprogramming to the clinic. Scientists are defining the minimal number of reprogramming genes necessary, identifying them, and trying to replace the introduced genes with chemicals. Yamanaka and others already have produced iPS cells without retroviruses and active c-Myc, innovations that should reduce the risk of cancer. Learning how reprogramming occurs in iPS cells may ultimately reveal new insights into the workings of ES cells.
Nuclear reprogramming has raised the possibility of changing easily accessible adult cells, such as those from skin, into tissue that might repair damage caused by a wide variety of injuries and diseaseswithout destroying embryos. Eventually, researchers would like to make patient-specific iPS cells. Because the same individual would donate the precursors of such cells and receive them as therapy, the cells would not spark an immune attack. iPS cells provide a way to study how some disorders progress from the earliest stages of a cell's development through full specialization, and they offer the opportunity to assess drug effectiveness and toxicity for a given person before subjecting that individual to treatment.
The conceptual and technical breakthroughs spearheaded by Gurdon and Yamanaka have unleashed previously unimagined strategies for combating diseases and probing normal development as well as pathological processes. They have launched an era in which scientists can reverse the clock to fashion cells that possess all possible fates from those that have arrived at a single one.
by Evelyn Strauss, Ph.D.